TY  - JOUR
AU  - Driessen, M T
AU  - Whalen, J
AU  - Seewoodharry Buguth, B
AU  - Vallejo-Aparicio, L A
AU  - Naya, I P
AU  - Asukai, Y
AU  - Alcázar-Navarrete, B
AU  - Miravitlles, M
AU  - García-Río, F
AU  - Risebrough, N A
PY  - 2018
DO  - 10.1186/s12931-018-0916-7
UR  - http://hdl.handle.net/10668/13216
T2  - Respiratory research
AB  - A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in symptomatic patients...
LA  - en
KW  - Bronchodilators
KW  - Chronic obstructive pulmonary disease
KW  - Cost effectiveness
KW  - Economic evaluation
KW  - Health resources
KW  - LAMA/LABA
KW  - National Healthcare System perspective
KW  - QALY
KW  - Spain
KW  - Utility
KW  - Aged
KW  - Benzoxazines
KW  - Benzyl Alcohols
KW  - Chlorobenzenes
KW  - Cost-Benefit Analysis
KW  - Cross-Over Studies
KW  - Drug Combinations
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - National Health Programs
KW  - Prospective Studies
KW  - Pulmonary Disease, Chronic Obstructive
KW  - Quinuclidines
KW  - Single-Blind Method
KW  - Spain
KW  - Tiotropium Bromide
TI  - Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
TY  - research article
VL  - 19
ER  -